Philippe Clevenbergh

Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial

J. Durant, Philippe Clevenbergh, Philippe Halfon et al. · The Lancet · 1999 · 761 citations

Health Sciences, Treatment And Prevention, Human Retrovirus +11

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

Richard G. Wunderink, Yuko Matsunaga, Mari Ariyasu et al. · The Lancet Infectious Diseases · 2020 · 432 citations

Antibiotics, Respiratory Infection, Sepsis +4

The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan

Victor DeGruttola, Lynn P. Dix, Richard T. D’Aquila et al. · Antiviral Therapy · 2000 · 330 citations · Full text

Pharmacotherapy, Antiviral Drug, Drug Resistance +19

Impact of Infectious Diseases Specialists and Microbiological Data on the Appropriateness of Antimicrobial Therapy for Bacteremia

B. Byl, Philippe Clevenbergh, Frédérique Jacobs et al. · Clinical Infectious Diseases · 1999 · 265 citations · Full text

Oral Antibiotics, Blood Culture Results, Antimicrobial Susceptibility +15

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

J. Durant, Philippe Clevenbergh, R. Garraffo et al. · AIDS · 2000 · 223 citations